Portfolio manager Dave Wagner stressed the need for further cost management and streamlined operations. With optimistic ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.

Pfizer has been looking for a fresh start after a rocky 2023, when its stock dropped more than 40% as some of the company's guidance proved overly optimistic. Last October, the company unveiled a cost ...

Pfizer reported higher-than-expected profit on Tuesday due to strong sales of COVID-19 treatment Paxlovid, an important win for Chief Executive Albert Bourla as he faces down activist investor ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...